MediSieve

MediSieve is a multi-award-winning medical device company developing Magnetic Blood Filtration (MBF), a platform technology for the treatment of blood-borne diseases by physically removing disease relevant targets directly from a patient’s bloodstream. MBF is an extracorporeal technology, similar to dialysis. A patient's blood is continuously circulated through an external blood loop containing the MediSieve system. Targeted magnetic particles (TB-MPs) are infused into the loop, binding specifically to disease-relevant targets in the patient's blood. The blood then flows through a magnetic filter which captures the particles and bound targets and the remainder of the blood returns to the patient unaffected; the TB-MPs never enter the patient’s body. MediSieve is based at the Imperial Incubator in White City, London. It has dedicated workshop and laboratory facilities (including capacity for ELISAs, Flow Cytometry and human blood testing) in which products are developed and validated.

MediSieve headquartered in Europe, operates in the Biotechnology, Health Care, Medical Device, Therapeutics sector. The company focuses on Biotechnology and has secured $1.7B in funding across 160 round(s). With a team of 11-50 employees, MediSieve is actively contributing to advancements in Biotechnology. Their latest funding round, Non Equity Assistance - MediSieve, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.